LOGIN
Two Infusions of Zoledronic Acid Reduce Femoral BMD Loss after THA Measured over 2 years
June 2013
Two Infusions of Zoledronic Acid Reduce Femoral BMD Loss after THA Measured over 2 years
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Effect of Zoledronic Acid on Reducing Femoral Bone Mineral Density Loss following Total Hip Arthroplasty Preliminary Results of a Prospective Randomized Trial
J Arthroplasty. 2013 Apr;28(4):671-5. doi: 10.1016/j.arth.2012.08.007. Epub 2012 Nov 8Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
51 randomized patients were evaluated to compare the effects of two infusions of Zoledronic acid (ZOL) against a placebo treatment on bone loss density after primary cementless total hip arthroplasty. During the 2 year study period, radiographic data demonstrated that infusions of ZOL at 2 weeks and 1 year after surgery had substantially and safely suppressed bone loss density loss in seven Gruen ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.